(E)-3-(3,4-dimethoxyphenyl)-N-methoxy-N-methylacrylamide | 689257-75-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(3,4-dimethoxyphenyl)-N-methoxy-N-methylacrylamide
• 英文别名: (2e)-3-(3,4-Dimethoxyphenyl)-n-methoxy-n-methylprop-2-enamide；(E)-3-(3,4-dimethoxyphenyl)-N-methoxy-N-methylprop-2-enamide
• CAS: 689257-75-8
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: FWYRXHZCGQXSLG-SOFGYWHQSA-N

物化性质

• 沸点：
  357.4±52.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-(3,4-dimethoxyphenyl)-N-methoxy-N-methylacrylamide 在 盐酸 、 sodium hydroxide 、 sodium hydride 、 二异丁基氢化铝 、 silver nitrate 作用下， 生成 ethyl [2-(3,4-dimethoxyphenyl)cyclopropyl]acetate
  参考文献：
  名称：

  Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization

  摘要：

  The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.020
• 作为产物：
  描述：

  3,4-二甲氧基肉桂酸 在 光气 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 (E)-3-(3,4-dimethoxyphenyl)-N-methoxy-N-methylacrylamide
  参考文献：
  名称：

  双不对称分子内氮杂-迈克尔反应：一种方便的合成喹诺西啶生物碱的策略

  摘要：

  设计了一种以不对称方式访问喹啉酮骨架的新方法。它涉及带有双烯酮部分的亚磺胺的两个连续的分子内氮杂-迈克尔反应，进而由单向交叉复分解反应产生。该序列以优异的产率和非对映体控制发生，应用于生物碱 lasubine I 和 myrtine 的全合成。

  DOI：

  10.1039/d1ob01488a

文献信息

• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：McDonald J. Joseph

  公开号：US20050209278A1

  公开（公告）日：2005-09-22

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及哌啶基和哌嗪基磺酰甲基羟肟酸，该类化合物在结构上抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这类羟肟酸通常对应以下结构式： （其中A1、A2、Y、E1、E2、E3和Rx如本说明书中所定义），还包括这类化合物的盐。这项发明还涉及这类羟肟酸的组合物、合成这类羟肟酸的中间体、制备这类羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的疾病（特别是病理性疾病）的方法。
• Asymmetric Gold(I)‐Catalyzed Tandem Hydroarylation–Nazarov Cyclization: Enantioselective Access to Cyclopentenones
  作者：Marta Solas、Samuel Suárez‐Pantiga、Roberto Sanz

  DOI：10.1002/anie.202207406

  日期：2022.8.26

  A new enantioselective version of the Nazarov cyclization is reported. The reaction design uses readily available alkenynones to trigger a gold(I)-catalyzed anti-Michael hydroarylation of the ynone followed by Nazarov cyclization. A chiral gold complex is able to control the absolute stereochemistry of the process. Cyclopenta[c]chromenones, which combine the 2H-chromene and cylopentanone cores, are

  报道了纳扎罗夫环化的新对映选择性版本。该反应设计使用容易获得的烯炔酮来触发炔酮的金(I)催化的反迈克尔加氢芳基化，然后进行纳扎罗夫环化。手性金络合物能够控制该过程的绝对立体化学。环戊[ c ]色酮结合了 2 H-色烯和环戊酮核心，合成时具有高产率和ee值。
• Catalytic Formal Homo-Nazarov Cyclization
  作者：Filippo De Simone、Julien Andrès、Riccardo Torosantucci、Jérôme Waser

  DOI：10.1021/ol802970g

  日期：2009.2.19

  The first catalytic method for the cyclization of vinyl-cyclopropyl ketones (formal homo-Nazarov reaction) is reported. Starting from activated cyclopropanes, heterocyclic, and carbocyclic compounds were obtained under mild conditions using Bronsted acid catalysts. Preliminary investigation of the reaction mechanism indicated a stepwise process.
• US6921767B2
  申请人：——

  公开号：US6921767B2

  公开（公告）日：2005-07-26